There will be an opportunity to stand on our own two feet as there is a Leronlimab alone dosing strategy. Special emphasis on “or reversing liver fibrosis.” No drug currently goes the distance with reduction in fibrosis. Dr Rector mentioned there were hints of this in the phase 2 study Cytodyn conducted. This would be a game changing drug in the MASH clinical space. Results this Fall…interesting days ahead.

“SMC will be conducting a twelve-week preclinical mouse study evaluating both 350 and 700 mg dose levels, alone and in combination with Resmetirom, a drug recently approved by the FDA. The study will evaluate leronlimab’s potential role in preventing and/or reversing liver fibrosis.”